Clinical microbiology meets phage at this year’s ECCMID

Issue 175 | May 13, 2022
7 min read
Capsid and Tail

At the 32nd ECCMID in Lisbon. From left to right: Silvia Wuerstle, Fabian Kunisch, Shawna McCallin, Rob Lavigne, Zuzanna Drulis-kawa, Jessica Neubauer. Credit: Silvia Wuerstle

For the first time since 2019 the yearly European Congress of Clinical Microbiology and Infectious Diseases (ECCMID) took place in-person. Jessica Neubauer, MSc student and Phage Directory volunteer, was there to report on all phings phage!

MAL Logo

This year is the 130th anniversary of the birth year of George Eliava, who founded the Eliava Research Institute in Tbilisi, Georgia.

PHAGE Journal will celebrate this event with a focused issue of phage therapy then and now!

If you would like to include your phage therapy work in this June Issue, please submit ASAP to be considered!

What’s New

Paper: Cleavage of viral DNA by restriction endonucleases stimulates the type II CRISPR-Cas immune response. Also check out this Spotlight on the paper.

Phage defense systemsResearch paper

Paper: An Optimal Lysis Time Maximizes Bacteriophage Fitness in Quasi-Continuous Culture

Phage fitnessPhage propagationResearch paper

Paper: Organizing the Global Diversity of Microviruses

MicrovirusesResearch paper

Preprint: Cyclic nucleotide-induced superhelical structure activates a bacterial TIR immune effector

Anti-phage systemMolecular BiologyPreprint

Blog: How Bacteria-Infecting Viruses Could Save Lives

BlogPhage Therapy

Latest Jobs

Post DocSynthetic biology
Postdoc: The Bikard lab at Institut Pasteur in Paris is seeking to hire postdoctoral researchers. We are investigating bacteria / bacteriophages interactions, and the genetic innovation that happens at this interface.
AquaticPost DocViral ecology
Postdoc: Dr. Mya Breitbart at the University of South Florida College of Marine Science invites applications to fill a Postdoctoral Research position working on aquatic viral ecology projects.
Antimicrobial developmentLaboratory Technician
Laboratory scientists at various levels of roles are invited to apply to join Fixed Phage to support the commercialisation of antibacterial solutions for humans and animal health.
AquaticAssistant ProfessorPhage biocontrol
Assistant Professor: The Rector of the Warsaw University of Life Sciences (SGGW) announces a competition for the employment of a research assistant at the Department of Biochemistry and Microbiology for the implementation of the international project: “Phage treatment and wetland technology as intervention strategy to prevent dissemination of antibiotic resistance in surface waters.”
MetagenomicsPost Doc
Postdoc: in the lab of Viral Metagenomics headed by Prof. Jelle Matthijnssens, University of Leuven in Belgium, on integration of bacterial and viral metagenomics datasets in the context of liver diseases.

Community Board

Anyone can post a message to the phage community — and it could be anything from collaboration requests, post-doc searches, sequencing help — just ask!

New NIAID request for applications: Partnerships for the Development of Novel Therapeutics To Combat Select Antibiotic Resistant Bacteria and Fungi (R01, Clinical Trial Not Allowed)

The purpose of this Funding Opportunity Announcement (FOA) is to solicit research applications for milestone-driven projects focused on preclinical development of lead candidate therapeutics and related countermeasures against antibiotic resistant Acinetobacter baumannii, Pseudomonas aeruginosa, Enterobacteriaceae, or Candida auris. Applications must include a Product Development Strategy attachment. Substantive investment by industrial participants is highly encouraged.

Funding opportunityAntibiotic Resistance

The first ESGNTA Online Course titled: “Personalised Phage Therapy: Basic Principles of Monitoring and Treatment”, will take place virtually on the 7-10th of June 2022.

It will include four sessions with cutting-edge scientific talks in the field of personalised phage therapy, including (1) therapeutic monitoring, (2) immune response to bacteriophages, (3) formulation and administration of bacteriophages for therapy, and (4) current state and prospects of oral phage therapy.

Register here by June 1 2022.

€50 for ESCMID members and €100 for non-members

Online coursePhage Therapy

Clinical microbiology meets phage at this year’s ECCMID

Profile Image
MSc Student
Böttcher Lab, University of Vienna
Twitter @biolojess

Molecular Biology, Teaching, Undergraduate research

Hello Phage World!
I’m Jess, a German master’s student at the University of Vienna. I’m currently working under Prof. Dr. Thomas Böttcher, poking bacteria until their prophages wake up.

As far as phage conferences go, there are a handful established favourites across the world where the who’s who meet to discuss those microbial viruses that we all know and love. Over the last years a new player entered the phield. Organised by ESCMID (the European Society of Clinical Microbiology and Infectious Diseases), the European Congress of Clinical Microbiology and Infectious Diseases (ECCMID for short) is a yearly four-day get-together of thousands of clinicians, researchers and industry representatives.

It was at this conference in 2018 in Madrid where I attended the session “Bacteriophages for antimicrobial therapy – what is the current evidence?” and heard about the history of phage therapy, the lessons learned from the PhagoBurn trial and the potential of phage therapy. For me this session was the moment I realized that my heart was irretrievably lost to all things phage.

Since the continued rise of antimicrobial resistance, an alternative to antibiotics for difficult to treat infections is becoming more and more pressing. ESCMID responded to this by including more and more sessions, posters and symposia regarding phages in their conference, and most recently by the creation of the new ESCMID Study Group for Non-traditional Antibacterial Therapy (ESGNTA). As the name indicates, they focus on various non-traditional antimicrobials from peptides to antibodies, and most importantly – phages. As part of their mission they have begun organizing several conference sessions to spread the word and to better integrate clinical and microbiological research. Which brings us to the 32nd ECCMID.

Picture it. Lisbon. The first in-person ECCMID since COVID-19 hit, with over 9,000 attendees on-site. A Master’s student one month into her thesis enters one of the first sessions of the conference.

Under the topic “New insights into phages: current challenges and future developments” Saija Kiljunen from Finland informs about preparation standards for personalized phage therapy, Krystyna Dabrowska shares her knowledge from the Polish Academy of Sciences about phage pharmacokinetics and the interplay with the immune system, Shawna McCallin from Switzerland gives an overview on clinical trials of the past and their challenges, and Tristan Ferry from France reports on the efficacy of phages. And I am falling in love all over again.

The phage phun continued the next day with another session organized by ESGNAT and the ESCMID Study Group for Antimicrobial Resistance Surveillance (ESGARS), titled “Fighting biofilm with non-traditional antibacterials”. Brushing off the remaining crumbs of my elevenses pastel de nata (those alone are worth the trip to Lisbon), I intently listened to Nuno Azevedo, who gave an insightful talk about antisense therapy and its effects against biofilms. Nuno was followed by Rob Lavigne, president of the International Society for Viruses of Microorganisms (ISVM), reviewing various phage-inspired leads for antimicrobials that go beyond classical phage therapy. Zuzanna Drulis-Kawa, President-Elect of ISVM, and Ran Nir-Paz, Chair of ESGNTA, were co-chairing the session. It might not come as a surprise to find several members of ISVM at ECCMID (the aforementioned Shawna McCallin being the Society’s Secretary). After all, ISVM’s mission includes creating a network of scientists working with microbial viruses and ECCMID offers a unique and vast assembly of scientists from all over the world.

Besides the presentations, there were countless (40+) posters featuring phage, ranging from phage isolation to prophages carrying immune evasion clusters. Combine that with the number of fascinating non-phage sessions and posters and industry booths handing out ‘Giant Microbes’ (I finally added Herpes and E. coli to my collection), and you get one happy scientist!

Overall it was a fantastic four days, in which I not only got a deeper insight into phage therapy and other phage-associated research, but most significant for me, I finally got to meet the people I previously have only known through a screen. For the last two years most conferences were held online, and the organizers did amazing jobs, yet nothing quite compares to trying to translate a Portuguese dinner menu together, before eventually resigning to the English version, or having a cup of coffee while discussing ongoing research.

Capsid & Tail

Follow Capsid & Tail, the periodical that reports the latest news from the phage therapy and research community.

We send Phage Alerts to the community when doctors require phages to treat their patient’s infections. If you need phages, please email us.

In collaboration with

Mary Ann Liebert PHAGE

Supported by

Leona M. and Harry B. Helmsley Charitable Trust

Crossref Member Badge